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Background: To understand immunological responses in chimpanzees vaccinated with live-attenuated 
vaccine (oral polio vaccine; OPV), serum neutralizing antibodies against poliovirus types 1, 2, and 3 
were investigated over time.  
Methods: The neutralizing antibody titers against poliovirus types 1, 2, and 3 were determined by 
microneutralization test using 100 ID50 of poliovirus types 1, 2, and 3 (Sabin strains).  
Results: Neutralizing antibodies against poliovirus types 1, 2, and 3 were detected in 85.7%, 71.4%, 
and 65% of the serum from 42 chimpanzees tested 9 years post-vaccination. The neutralizing 
antibody titers in chimpanzees were similar to the documented levels in human studies as an indicator 
of vaccine efficacy.  
Conclusions: This study reveals persistence of neutralizing antibodies in chimpanzees for at least 9 
years after vaccination with OPV. This first study in chimpanzees provides useful information for the 





Poliomyelitis is a life-threatening acute paralytic disease caused by poliovirus (PV) [2, 3, 19, 32, 33, 
39]. Poliovirus is highly infectious belonging to the genus Enterovirus in the family Picornaviridae with 
three distinct serotypes (type 1, 2, and 3) [3]. Poliovirus is mainly transmitted through the fecal-oral 
route as the virus replicates efficiently in the intestinal tract. In humans, it is typically shed with the 
stool for 2–4 weeks. Feces can serve as a source of contamination of water, milk, and food. 
Houseflies can passively transfer poliovirus from feces to food [13]. Virus transmission is facilitated by 
poor sanitation and factors such as crowding, low levels of hygiene, water quality, and sewage-
handling facilities. Humans are considered as the sole reservoir for poliovirus. The three serotypes 
are able to cause human infection with incubation periods of 5–35 days. Poliomyelitis is an acute viral 
infection, which ranges in severity from a non-specific illness to paralysis with permanent disability and 
death. Historically, poliovirus paralyzed and killed high numbers of people before the licensing of 
inactivated poliovirus vaccine (IPV) in 1955 and Oral Polio Vaccine (OPV) in 1962 and introduction of 
vaccination worldwide [33]. The IPV is prepared by growing the poliovirus in monkey kidney tissue 
culture (vero cell line) and inactivated with formaldehyde [6]. It contains 2-phenoxyethanol, neomycin, 
streptomycin, polymyxin B (used to prevent bacterial and fungal growth), and all three serotypes of 
poliovirus [7]. The vaccine is effective in inducing circulating antibodies in blood, thus preventing polio 
virus in the gut from entering and replicating in the central nervous system [39]. Whereas trivalent 
OPV is a live-attenuated vaccine containing all three serotypes of poliovirus in a ratio of 10:1:6 [7, 26]. 
  
These attenuated PV strains replicate in the human gut inducing mucosal immunity that inhibits 
replication of the virus in the gastrointestinal tract [7, 26]. The OPV produces long-lasting mucosal 
immunity by stimulating the formation of IgA antibodies in the intestine and also serum antibodies in 
the bloodstream [35].  
 
Although humans are the only known natural reservoirs of poliovirus, non-human primates, especially 
apes (chimpanzees and gorillas), are susceptible [10, 11]. Macaques, African green monkeys and 
Cebus spp. can be experimentally infected with poliovirus but do not generally develop a paralytic 
disease when infected by the peripheral route [36]. However, paralytic disease 
because of poliovirus infections via human contacts has been reported in captive chimpanzees, 
orangutans, gorillas, and colobus monkeys [1, 3, 10, 17, 20, 21]. Antibodies and shedding of virus 
have been found in imported animals [10], and some chimpanzees may act as symptomless carriers 
[4]. A suspected poliovirus outbreak in wild apes was reported in Kasakela Community of the Gombe 
chimpanzee population research group in Tanzania in 1966 where six chimpanzees died from the 
disease and at least six others were paralyzed lifelong [14–16, 22]. A similar outbreak among the 
free-ranging chimpanzees was reported in Beni, Zaire, with at least seven of 48 chimpanzees in the 
study group handicapped by limb paresis [27]. Analysis of chimpanzee skeletons of two adult females 
with longterm, partial paralysis and a group of unaffected adult Gombe chimpanzees revealed that 
poliovirus caused considerable asymmetries in the skeleton [31]. It was not clarified whether the 
outbreak was part of a natural cycle within the great ape population or a result of poliovirus 
transmission from humans. Chimpanzees in Gombe National Park (25 km2) inhabit a potentially 
contaminated environment from human communities living close to the park in the north and south 
sharing the same resources such as water [16, 37]. Poliovirus was widespread in the local human 
population during the 1960s and therefore transmission from humans was discussed as the most likely 
route when the chimpanzee community was habituated for research [22, 37]. Chimpanzees are 
susceptible to almost all human pathogens, so close proximity increases the risk of disease 
transmission [28]. Hence, it was recommended that chimpanzees and other apes in captive facilities 
should be vaccinated against poliovirus to avoid the risk of direct or indirect transmission from humans 
[25, 38, 40].  
 
Therefore, primates in sanctuaries are generally vaccinated with the human poliovirus vaccine. 
However, as yet no long-term studies have been undertaken to evaluate immunological responses in 
vaccinated apes, and all recommendations on vaccination strategies are based on human studies. 
The American Zoo and Aquarium Association Species Survival Plan recommend 
vaccination of captive great apes with IPV at 12–13 months of age with a booster once at 1–2 years 
[25, 38]. Captive facilities and sanctuaries in Africa are using OPV in apes following human 
vaccination schedules, but variable regimes are used. To complement the Global Polio Eradication 
Program, vaccination programs of non-human primates in sanctuaries have to be adapted to the 
current state of art.  
 
In this study, we show that OPV induces a long-lasting immunity against poliovirus in sanctuary 
chimpanzees in Uganda, and we discuss the future use of IPV for the vaccination of non-human 






















Ngamba Island Chimpanzee Sanctuary which started in 1998 is located on Ngamba Island (S 000 
06/E 32°39, 0.46 km2, 1160 m above sea level) and is part of the Koome group of islands in Mukono 
District, Uganda, lies 23 km off Entebbe in the northwest of Lake Victoria. Ngamba Island Chimpanzee 
Sanctuary currently cares for 44 rescued orphan chimpanzees on 100 hectares of secondary rain 





The study was conducted on 42 orphan chimpanzees that live in a semi-captive management system 
on Ngamba Island Chimpanzee Sanctuary. The group consisted of 23 females and 19 males with age 
group categorized as follows: four infants (1–5 years), six juveniles (6–8 years), 12 sub-adults (9–11 
years), and 20 adults (12 years and more). They have lived on the island for varying lengths of time 
after being rescued from illegal traders and poachers since 1998. Rescued individuals are held in 
quarantine for 90 days during which period they are vaccinated against polioviruses using OPV (0.1 ml 
of Sabin Polio, Panacea Biotec Ltd, A-241 Okhla Indi.Area-1, Delhi-110020). Routine management 
of these rescued chimpanzees on the island exposes them to direct human contact by caregivers and 
veterinarians and indirectly to tourists, school groups, local community members, and researchers. 





Blood was collected from all chimpanzees during our annual medical checks in February, 2007. 
Individual animal welfare is of paramount importance and is part of our standard operating procedures; 
hand-held intramuscular injection of anesthetic drugs using a combination of ketamine (3 mg/kg) and 
meditomidine (0.03 mg/kg) is administered to minimize stress. Blood (7.5 ml) was taken from the 
femoral vein using EDTA Vacutainer tubes. Plasma/serum was extracted by centrifugation and stored 
at -80°C at the Uganda Virus Research Institute until transported on dry ice to Robert Koch-Institut, 
Berlin, Germany, for analysis. Retrospective serum collected in 2001 and 2005 and stored at -40°C 
was included in the assessment of antibody titers. This study was approved by Chimpanzee Sanctuary 
&Wildlife Conservation Trust as part of the veterinary preventive healthcare management, and 
research and export permits were issued by Uganda Wildlife Authority, Uganda National Council of 





The methods for the determination of the neutralizing antibody titers against poliovirus types 1, 2, and 
3 have been described elsewhere [41]. Briefly, the microneutralization test using 100 ID50 poliovirus 
(Sabin strains) was performed according to WHO guidelines [41]. A positive control using an in-house 
reference serum (IHR) of known neutralizing activity was included in each test to control reproducibility 
of results. The international standard serum (a preparation of pooled human serum) containing 25 IU, 
50 IU, and 5 IU for polioviruses 1, 2, and 3, respectively, was used to calibrate the potency of the IHR 
[9]. Before laboratory testing, serum was inactivated for 30 minutes at 56°C in a water bath. Afterward, 
twofold dilutions of serum starting from 1:4 to 1:512 were incubated for 3 hours at 36°C in duplicate 
with 100 TCID50 of the corresponding Sabin-type poliovirus. Human rhabdomyosarcoma cell 
suspensions were added, and results were scored after 7 days of culture. A serum dilution of ‡1:4 











The vaccinated chimpanzees with OPV under this study were found with neutralizing antibodies 
against poliovirus types 1, 2, and 3 detected in 85.7%, 71.4%, and 65%, respectively, of the tested 
serum 9 years post-vaccination. Of the studied chimpanzees, five had no neutralizing antibodies 
(<1:4) against poliovirus types 1, 2, and 3, including the captive-born infant that had not been 
vaccinated. Percentages for neutralizing antibodies from 2001 to 2005 serum were not computed 
because of high levels of bacterial contamination in the samples. For non-contaminated serum 
samples (results not shown here), neutralizing antibody titers were comparable with those obtained 
from 2007. The three recent orphan arrivals (Kityo, Rutoto and Rambo) had multiple vaccinations 
(more than three with OPV) while in quarantine as shown in Table 1, but the neutralizing antibodies 





We present for the first time a vaccination success of captive chimpanzees with OPV. The neutralizing 
antibody titers found in chimpanzees are similar to those reported in human studies [9], indicating a 
high level of protection in the OPV-vaccinated chimpanzees. This study also reveals persistence of 
neutralizing antibodies for at least 9 years post-vaccination with OPV. The percentage of neutralizing 
antibodies detected against poliovirus types 2 and 3 (71.4% and 65%) was generally lower than those 
for poliovirus 1 (85.7%). This is in agreement with serological studies in humans, showing lower 
antibody titers for poliovirus types 2 and 3 [8, 9]. Four chimpanzees had no neutralizing antibodies 
(<1:4) against poliovirus types 1, 2, and 3 despite records showing they had been vaccinated at least 
once. This may be because of other viral or helminth intestinal infections prohibiting uptake of OPV as 
reported in developing countries where OPV has been shown to be less potent in inducing humoral 
immunity. Repeated vaccinations up to 5–10 times are hence required to protect all children [23, 30, 
32, 34].  
 
It is known that immunity to poliomyelitis is dependent on humoral neutralizing antibodies, both after 
natural infection and after vaccination. Hence, presence of antibodies beyond a threshold antibody 
level is an indication of protective immunity in case of poliomyelitis. It has been shown that enterovirus 
infections also induce T-cell immunity [24], but little information is available about the cellular immunity 
in great apes. It is not even clear whether these individual chimpanzees with low titers or no detectable 
antibodies are susceptible to infection as it is with humans.  
 
Trivalent OPV is recommended by Expanded Program on Immunisation as a vaccine of choice for 
eradication of poliomyelitis because of its low cost, ease of administration, superiority in conferring 
intestinal immunity, and the potential to infect household and community contacts secondarily [12]. 
However, it 
has been reported that OPV is less potent in inducing humoral immunity in developing countries where 
the infection of the intestines by other viruses may prohibit the intake of OPV. Further, the continuous 
use of OPV may result in increase vaccine-associated paralytic polio, circulating vaccine-derived 
polioviruses (cVDPV) and those originating from immune-deficient vaccine-derived polioviruses 
(iVDPV) [26, 29]. Therefore, the IPV, which is already widely used in developed countries, should play 
the major role during the endgame of polio eradication and thereafter.  
 
Hence, poliovirus vaccination of non-human primates, especially apes in captive facilities (zoos and 
sanctuaries), should be evaluated along with the global eradication program and follow the established 
WHO global action for laboratory containment of wild polioviruses [42, 43]. This study shows that OPV 
induces high levels of protective immunity in chimpanzees, but future use of OPV in captive apes 
should be assessed. As vaccine-derived strains (VDPV) may be excreted in feces for several weeks 
and even years (in the case of immunodeficient patients), it serves as a source of dissemination of 
polioviruses and the cause of poliomyelitis [18, 26, 29]. Sequence drift has been shown in VDPV as an 
indication of prolonged replication of the vaccine strain either in one individual or in the community [5, 
26, 29]. Although it is not known for how long the polioviruses are excreted in feces of vaccinated 
apes, it may be risky to continue to use OPV in apes, and IPV may be safer to use at this point. The 
results presented in this study will serve as a baseline data for more studies to be undertaken in 
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Cutoff at dilution of 1:4 in serum. 
1Castrated male; Ct: results could not be read because of bacterial contamination. 
  
